Clinical Policy Bulletin: Breast Reconstructive Surgery
Aetna considers reconstructive breast surgery medically necessary after a medically necessary mastectomy or a medically necessary lumpectomy that results in a significant deformity (i.e., mastectomy or lumpectomy for treatment of or prophylaxis for breast cancer and mastectomy or lumpectomy performed for chronic, severe fibrocystic breast disease, also known as cystic mastitis, unresponsive to medical therapy). Medically necessary procedures include capsulectomy, capsulotomy, implantation of Food and Drug Administration (FDA)-approved internal breast prosthesis, mastopexy, insertion of breast prostheses, the use of tissue expanders, or reconstruction with a latissimus dorsi (LD) myocutaneous flap, Ruben’s flap, superficial inferior epigastric perforator (SIEP) flap, superior or inferior gluteal free flap, transverse upper gracilis (TUG) flap, transverse rectus abdominis myocutaneous (TRAM) flap, deep inferior epigastric perforator (DIEP) flap, profunda artery perforator flap, or similar procedures, including skin sparing techniques. Aetna considers the body lift perforator flap technique for breast reconstruction experimental and investigational because there is insufficient evidence to support the effectiveness of this approach.
Harvesting (via of lipectomy or liposuction) and grafting of autologous fat as a replacement for implants for breast reconstruction, or to fill defects after breast conservation surgery or other reconstructive techniques, is considered medically necessary.
The use of the following acellular dermal matrices are considered medically necessary for breast reconstruction: Alloderm (LifeCell Corp., Branchburg, NJ), Alloderm-RTU (LifeCell Corp., Branchburg, NJ), FlexHD (Musculoskeletal Transplant Foundation/Ethicon, Inc., Somerville, NJ), DermaMatrix (Musculoskeletal Transplant Foundation/Synthes CMF, West Chester, PA), AlloMax (formerly NeoForm) (Davol, Inc., Warwick, RI), Strattice (LifeCell Corp., Branchburg, NJ) and SurgiMend (TEI Biosciences, Boston, MA).
Aetna considers associated nipple and areolar reconstruction and tattooing of the nipple area medically necessary. Reduction (or some cases augmentation) mammoplasty and related reconstructive procedures on the unaffected side for symmetry are also considered medically necessary.
Aetna considers breast reconstructive surgery to correct breast asymmetry cosmetic except for: (i) surgical correction of chest wall deformity causing functional deficit in Poland syndrome when criteria are met in CPB 0272 - Pectus Excavatum and Poland’s Syndrome: Surgical Correction; or (ii) repair of breast asymmetry due to a medically necessary mastectomy or a medically necessary lumpectomy that results in a significant deformity. Medically necessary procedures on the non-diseased/unaffected/contralateral breast to produce a symmetrical appearance may include areolar and nipple reconstruction, areolar and nipple tattooing, augmentation mammoplasty, augmentation with implantation of FDA-approved internal breast prosthesis when the unaffected breast is smaller than the smallest available internal prosthesis, breast implant removal and subsequent re-implantation when performed to produce a symmetrical appearance, breast reduction by mammoplasty or mastopexy, capsulectomy, capsulotomy, and reconstructive surgery revisions to produce a symmetrical appearance; or (iii) prompt* repair of breast asymmetry due to trauma. (*Note: See CPB 0031 - Cosmetic Surgery for criteria related to surgical repair of cosmetic disfigurement due to trauma).
Aetna considers Biodesign Nipple Reconstruction Cylinder experimental and investigational becasue its effectiveness has not been established.
Breast reconstruction using autologous tissue is most commonly performed using the transverse rectus abdominis myocutaneous (TRAM) flap. This flap has been in use for 20 years and has provided excellent aesthetic results. However, a drawback of the TRAM flap is related to donor site morbidity of the abdomen. The pedicle TRAM flap frequently requires use of the entire rectus abdominis muscle, while the free TRAM flap requires use of as little as a postage-stamp size portion of the muscle. Abdominal complications resulting from a sacrifice of all or a portion of the rectus abdominis muscle include a reduction in abdominal strength (10 to 50 %), abdominal bulge (5 to 20 %), and hernia (less than 5 %).
Perforator flaps have gained increasing attention with the realization that the muscle component of the TRAM flap does not add to the quality of the reconstruction and serves only as a carrier for the blood supply to the flap. Thus, the concept of separating the flap (skin, fat, artery, and vein) from the muscle was realized as a means of minimizing the morbidity related to the abdominal wall and maintaining the aesthetic quality of the reconstruction. The deep inferior epigastric perforator (DIEP) flap was introduced in the early 1990's and is identical to the free TRAM flap except that it contains no muscle or fascia. Use of this flap has been popular in the Europe for a number of years and is now gaining popularity in the United States. The DIEP flap has been performed at Johns Hopkins for several years. Candidates for this operation are similar to those for the free TRAM in that there must be adequate abdominal fat to create a new breast. However, caution must be exercised in performing this technique in women who require large volume reconstruction to prevent the occurrence of fat necrosis or hardening of the new breast. The operation can be performed immediately following mastectomy or on a delayed basis. Performance of this operation is slightly more difficult than the free TRAM flap because it requires meticulous dissection of the perforating vessels from the muscle.
Deep inferior epigastric perforator flaps tend to have less robust blood flow than is typical with a standard TRAM reconstruction, so careful patient selection is important. In patients who are non-smokers, who require no more than 70 % of the TRAM flap skin paddle to make a breast of adequate size, and who have at least 1 perforating vessel greater than 1-mm in diameter with a detectable pulse, the incidence of flap complications reportedly is similar to that seen in standard free TRAM flap reconstruction.
Superior gluteal artery perforator (SGAP) flaps may be performed on women who are not candidates for a TRAM flap or who have had a failed TRAM flap. Thin women who may not have much tissue in the lower abdominal area often have an adequate amount of tissue in the gluteal region. The inferior gluteal artery perforator (SGAP) flap shares the same indications as the superior gluteal flap, namely the inability to use the TRAM flap and an abundance of soft tissue in the gluteal region.
Poland syndrome is an extremely rare developmental disorder that is present at birth (congenital). It is characterized by absence (agenesis) or under-development (hypoplasia) of certain muscles of the chest (e.g., pectoralis major, pectoralis minor, and/or other nearby muscles), and abnormally short, webbed fingers (symbrachydactyly). Additional findings may include underdevelopment or absence of 1 nipple (including the darkened area around the nipple [areola]) and/or patchy hair growth under the arm (axilla). In females, 1 breast may also be under-developed (hypoplastic) or absent (amastia). In some cases, affected individuals may also exhibit under-developed upper ribs and/or an abnormally short arm with under-developed forearm bones (i.e., ulna and radius) on the affected side. In most cases, physical abnormalities are confined to one side of the body (unilateral). In approximately 75 % of the cases, the right side of the body is affected. The range and severity of symptoms may vary from case to case. The exact cause of Poland syndrome is not known.
Autologous fat grafting (or lipomodeling) uses the patient's own fat cells to replace volume after breast reconstruction, or to fill defects in the breast following breast-conserving surgery (NICE, 2012). It can be used on its own or as an adjunct to other reconstruction techniques. The procedure aims to restore breast volume and contour without the morbidity of other reconstruction techniques. With the patient under general or local anesthesia, fat is harvested by aspiration with a syringe and cannula, commonly from the abdomen, outer thigh or flank. The fat is usually washed and centrifuged before being injected into the breast. Patients subsequently undergo repeat treatments (typically 2 to 4 sessions) (NICE, 2012). Autologous fat grafting may be delayed for a variable period of time after mastectomy. Most of the evidence for the use of autologous fat grafting in breast reconstruction is as a technique to repair contour defects and deformities. There is less information about the use of autologous fat grafting for complete breast reconstruction.
Guidance from the National Institute for Health and Clinical Excellence (NICE, 2012) states that current evidence on the efficacy of breast reconstruction using lipomodelling after breast cancer treatment is adequate and the evidence raises no major safety concerns. The guidance noted that there is a theoretical concern about any possible influence of the procedure on recurrence of breast cancer in the long term, although there is no evidence of this in published reports. The guidance notes that a degree of fat resorption is common in the first 6 months and there have been concerns that it may make future mammographic images more difficult to interpret.
A technology assessment on autologous fat injection for breast reconstruction prepared for the Australian and New Zealand Horizon Scanning Network (Humphreys, 2008) found that the technique has the potential to improve some contour defects; however, the results appear to be highly variable, with 2 case series finding that following autologous fat injection between 21 % and 86.5 % of patients showed substantial improvement at post-operative assessment. Patient satisfaction with the procedure was not reported. The assessment stated that longer-term follow-up is needed to determine how much of the injected fat survives and how much is eventually re-absorbed by the body. There are also important safety issues with the procedure, especially in association with the lipo-necrotic lumps that can form in the breast from the injected fat. Both case series reported this to occur in approximately 7 % of cases, and there is concern that such lumps will impede future cancer detection.
Hyakusoku et al (2009) reported several cases of complications following fat grafting to the breast. These investigators retrospectively reviewed 12 patients who had received autologous fat grafts to the breast and required breast surgery and/or reconstruction to repair the damage presenting between 2001 and 2007. All 12 patients (mean age of 39.3 years) had received fat injections to the breast for augmentation mammaplasty for cosmetic purposes. They presented with palpable indurations, 3 with pain, 1 with infection, 1 with abnormal breast discharge, and 1 with lymphadenopathy. Four cases had abnormalities on breast cancer screening. All patients underwent mammography, computed tomography, and magnetic resonance imaging to evaluate the injected fats. The authors concluded that autologous fat grafting to the breast is not a simple procedure and should be performed by well-trained and skilled surgeons. Patients should be informed that it is associated with a risk of calcification, multiple cyst formation, and indurations, and that breast cancer screens will always detect abnormalities. Patients should also be followed-up over the long-term and imaging analyses (e.g., mammography, echography, computed tomography, and magnetic resonance imaging) should be performed.
The American Society of Plastic Surgeons (ASPS) fat grafting task force (Gutowski, 2009) concluded that autologous fat grafting is a promising and clinically relevant research topic. The current fat grafting literature is limited primarily to case studies, leaving a tremendous need for high-quality clinical studies.
Mizuno and Hyakusoku (2010) stated that recent technical advances in fat grafting and the development of surgical devices such as liposuction cannulae have made fat grafting a relatively safe and effective procedure. However, guidelines issued by the ASPS in 2009 announced that fat grafting to the breast is not a strongly recommended procedure, as there are limited scientific data on the safety and efficacy of this particular type of fat transfer. Recent progress by several groups has revealed that multi-potent adult stem cells are present in human adipose tissue. This cell population, termed adipose-derived stem cells (ADSC), represents a promising approach to future cell-based therapies, such as tissue engineering and regeneration. In fact, several reports have shown that ADSC play a pivotal role in graft survival through both adipogenesis and angiogenesis. Although tissue augmentation by fat grafting does have several advantages in that it is a non-invasive procedure and results in minimal scarring, it is essential that such a procedure be supported by evidence-based medicine and that further research is conducted to ensure that fat grafting is a safe and effective procedure.
Acellular dermal matrices are considered a standard-of-care as an adjunct to breast reconstruction. The clinical literature on acellular dermal matrix product in breast reconstruction primarily consists of single institution case series focusing on surgical technique. Much of the early literature focused on AlloDerm brand of acellular dermal matrix, since this product was first to market, but more recent literature has considered other acellular dermal matrix products. Recent literature has provided comparisons of AlloDerm to certain other acellular dermal matrix products, with the authors concluding that there is no significant difference among products (see, e.g., Ibrahim, et al., 2013; Cheng, et al., 2012). While different acellular dermal matrix products are processed differently, these appear to result in minor differences in performance in breast reconstruction.
The Biodesign Nipple Reconstruction Cylinder is intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. It is supplied sterile and is intended for 1-time use. There is a lack of evidence regading the clincial value of this product in breast reconstructive surgery.
Llewellyn-Bennett et al (2012) noted that latissimus dorsi (LD) flap procedures comprise 50 % of breast reconstructions in the United Kingdom. They are frequently complicated by seroma formation. In a randomized study, these researchers investigated the effect of fibrin sealant (Tisseel(®)) on total seroma volumes from the breast, axilla and back (donor site) after LD breast reconstruction. Secondary outcomes were specific back seroma volumes together with incidence and severity of wound complications. Consecutive women undergoing implant-assisted or extended autologous LD flap reconstruction were randomized to either standard care or application of fibrin sealant to the donor-site chest wall. All participants were blinded for the study duration but assessors were only partially blinded. Non-parametric methods were used for analysis. A total of 107 women were included (sealant = 54, control = 53). Overall, back seroma volumes were high, with no significant differences between control and sealant groups over 3 months. Fibrin sealant failed to reduce in-situ back drainage volumes in the 10 days after surgery, and did not affect the rate or volume of seromas following drain removal. The authors concluded that the findings of this randomized study, which was powered for size effect, failed to show any benefit from fibrin sealant in minimizing back seromas after LD procedures.
Allen et al (2012) stated that the use of perforator flaps has allowed for the transfer of large amounts of soft tissue with decreased morbidity. For breast reconstruction, the DIEP flap, the superior and inferior gluteal artery perforator flaps, and the transverse upper gracilis flap are all options. These investigators presented an alternative source using posterior thigh soft tissue based on profunda artery perforators, termed the profunda artery perforator flap. Pre-operative imaging helped identify posterior thigh perforators from the profunda femoris artery. These are marked, and an elliptical skin paddle, approximately 27 × 7 cm, is designed 1 cm inferior to the gluteal crease. Dissection proceeded in a supra-fascial plane until nearing the perforator, at which point sub-fascial dissection was performed. The flap has a long pedicle (approximately 7 to 13 cm), which allowed more options when performing anastomosis at the recipient site. The long elliptical shape of the flap allowed coning of the tissue to form a more natural breast shape. All profunda artery perforator flaps have been successful. The donor site was well-tolerated and scars have been hidden within the gluteal crease. Long-term follow-up is needed to evaluate for possible fat necrosis of the transferred tissue. The authors presented a new technique for breast reconstruction with a series of 27 flaps. They stated that this is an excellent option when the abdomen is not available because of the long pedicle, muscle preservation, ability to cone the tissue, and hidden scar.
Tanna et al (2013) presented the findings of the largest series of microsurgical breast reconstructions following nipple-sparing mastectomies. All patients undergoing nipple-sparing mastectomy with microsurgical immediate breast reconstruction treated at New York University Medical Center (2007 to 2011) were identified. Patient demographics, breast cancer history, intraoperative details, complications, and revision operations were examined. Descriptive statistical analysis, including t-test or regression analysis, was performed. In 51 patients, 85 free flap breast reconstructions (n = 85) were performed. The majority of flaps were performed for prophylactic indications [n = 55 (64.7 %)], mostly through vertical incisions [n = 40 (47.0 %)]. Donor sites included abdominally based [n = 66 (77.6 %)], profunda artery perforator [n = 12 (14.1 %)], transverse upper gracilis [n = 6 (7.0 %)], and superior gluteal artery perforator [n = 1 (1.2 %)] flaps. The most common complications were mastectomy skin flap necrosis [n = 11 (12.7 %)] and nipple necrosis [n = 11 (12.7 %)]. There was no correlation between mastectomy skin flap or nipple necrosis and choice of incision, mastectomy specimen weight, body mass index, or age (p > 0.05). However, smoking history was associated with nipple necrosis (p < 0.01). The authors concluded that the findings of this series represented a high-volume experience with nipple-sparing mastectomy followed by immediate microsurgical reconstruction. When appropriately executed, it can deliver low complication rates.
Levine et al (2013) stated that recent evolutions of oncologic breast surgery and reconstruction now allow surgeons to offer the appropriate patients a single-stage, autologous tissue reconstruction with the least donor-site morbidity. These investigators presented their series of buried free flaps in nipple-sparing mastectomies as proof of concept, and explored indications, techniques, and early outcomes from their series. From 2001 to 2011, a total of 2,262 perforator-based free flaps for breast reconstruction were reviewed from the authors' prospectively maintained database. There were 338 free flaps performed on 215 patients following nipple-sparing mastectomy, including 84 patients who underwent breast reconstruction with 134 buried free flaps. Ductal carcinoma in-situ and BRCA-positive were the most common diagnoses, in 26 patients (30.9 %) each. The most common flaps used were the DIEP (77.6 %), transverse upper gracilis (7.5 %), profunda artery perforator (7.5 %), and superficial inferior epigastric artery flaps (3.7 %). An implantable Cook-Swartz Doppler was used to monitor all buried flaps. Fat necrosis requiring excision was present in 5.2 %of breast reconstructions, and there were 3 flap losses (2.2 %); 78 flaps (58.2 %) underwent minor revision for improved cosmesis; 56 (41.8 %) needed no further surgery. The authors concluded that nipple-sparing mastectomy with immediate autologous breast reconstruction can successfully and safely be performed in a single stage; however, the authors are not yet ready to offer this as their standard of care.
Healy and Allen (2013) noted that it is over 20 years since the inaugural DIEP flap breast reconstruction. These investigators reviewed the type of flap utilized and indications in 2,850 microvascular breast reconstruction over the subsequent 20 years in the senior author's practice (Robert J. Allen). Data were extracted from a personal logbook of all microsurgical free flap breast reconstructions performed between August 1992 and August 2012. Indication for surgery; mastectomy pattern in primary reconstruction; flap type, whether unilateral or bilateral; recipient vessels; and adjunctive procedures were recorded. The DIEP was the most commonly performed flap (66 %), followed by the superior gluteal artery perforator flap (12 %), superficial inferior epigastric artery perforator flap (9 %), inferior gluteal artery perforator flap (6 %), profunda artery perforator flap (3 %), and transverse upper gracilis flap (3 %). Primary reconstruction accounted for 1,430 flaps (50 %), secondary 992 (35 %), and tertiary 425 (15 %). As simultaneous bilateral reconstructions, 59 % flaps were performed. With each flap, there typically ensues a period of enthusiasm which translated into surge in flap numbers. However, each flap has its own nuances and characteristics that influence patient and physician choice. Of note, each newly introduced flap, either buttock or thigh, results in a sharp decline in its predecessor. In this practice, the DIEP flap has remained the first choice in autologous breast reconstruction.
Weichman et al (2013) examined patients undergoing autologous microsurgical breast reconstruction with and without the adjunct of autologous fat grafting to clearly define utility and indications for use. A retrospective review of all patients undergoing autologous breast reconstruction with microvascular free flaps at a single institution between November 2007 and October 2011 was conducted. Patients were divided into 2 groups as follows: (i) those requiring postoperative fat grafting and (ii) those not requiring fat grafting. Patient demographics, indications for surgery, history of radiation therapy, patient body mass index, mastectomy specimen weight, need for rib resection, flap weight, and complications were analyzed in comparison. A total of 228 patients underwent 374 microvascular free flaps for breast reconstruction. One hundred (26.7 %) reconstructed breasts underwent post-operative fat grafting, with an average of 1.12 operative sessions. Fat was most commonly injected in the medial and superior medial poles of the breast and the average volume injected was 147.8 ml per breast (22 to 564 ml). The average ratio of fat injected to initial flap weight was 0.59 (0.07 to 1.39). Patients undergoing fat grafting were more likely to have had DIEP and profunda artery perforator flaps as compared to muscle-sparing transverse rectus abdominis myocutaneous. Patients additionally were more likely to have a prophylactic indication 58 % (n = 58) versus 42 % (n = 117) (p = 0.0087), rib resection 68 % (n = 68) versus 54 % (n = 148) (p < 0.0153), and acute post-operative complications requiring operative intervention 7 % (n = 7) versus 2.1 % (n = 8) (p < 0.0480). Additionally, patients undergoing autologous fat grafting had smaller body mass index, mastectomy weight, and flap weight. The authors concluded that fat grafting is most commonly used in those breasts with rib harvest, DIEP flap reconstructions, and those with acute post-operative complications. It should be considered a powerful adjunct to improve aesthetic outcomes in volume-deficient autologous breast reconstructions and additionally optimize contour in volume-adequate breast reconstructions.
The “body lift” perforator flap technique allows for a double fat layer in each breast when both breasts are being reconstructed. This is offered to the thin patient with ample breasts in the setting of bilateral mastectomy when volume preservation and projection are desired, yet the fat deposits in the waist and tummy are minimal. A body lift incision design in the waist gives both a tummy tuck effect and a lift of the buttocks in the donor site. There is currently insufficient evidence to support the use of the body lift perforator flap technique for breast reconstruction.
DellaCroce et al (2012) stated that for patients with a desire for autogenous breast reconstruction and insufficient abdominal fat for conventional abdominal flaps, secondary options such as gluteal perforator flaps or latissimus flaps are usually considered. Patients who also have insufficient soft tissue in the gluteal donor site and preference to avoid an implant, present a vexing problem. These researchers described an option that allows for incorporation of 4independent perforator flaps for bilateral breast reconstruction when individual donor sites are too thin to provide necessary volume. They presented their experience with this technique in 25 patients with 100 individual flaps over 5 years. The “body lift” perforator flap technique, using a layered deep inferior epigastric perforator/gluteal perforator flap combination for each breast, was performed in this patient set with high success rates and quality aesthetic outcomes over several years. Patient satisfaction was high among the studied population. The authors concluded that the body lift perforator flap breast reconstruction technique can be a reliable, safe, but technically demanding solution for patients seeking autogenous breast reconstruction with otherwise inadequate individual fatty donor sites. This sophisticated procedure overcomes a limitation of autogenous breast reconstruction for these patients that otherwise resulted in a breast with poor projection and overall volume insufficiency. The harvest of truncal fat with a circumferential body lift design gave the potential added benefit of improved body contour as a complement to this powerful breast reconstructive technique.
Also, UpToDate reviews on “Principles of grafts and flaps for reconstructive surgery” (Morris, 2013) and “Breast reconstruction in women with breast cancer” (Nahabedian, 2013) do not mention the body lift perforator flap technique as a management tool for breast reconstruction.
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes covered if selection criteria are met:
Other CPT codes related to the CPB:
19120 - 19126
19300 - 19307
21740 - 21743
HCPCS codes covered if selection criteria are met:
Mesh (implantable) [AlloMax]
Prosthesis, breast (implantable)
Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm
L8020 - L8039
Implantable breast prosthesis, silicone or equal
Alloderm, per square centimeter
Flex HD, Allopatch HD, or Matrix HD, per square centimeter
Strattice TM, per sq cm
Breast reconstruction with gluteal artery perforator (GAP) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral
Breast reconstruction of a single breast with "stacked" deep inferior epigastric perforator (DIEP) flap(s) and/ or gluteal artery perforator (GAP) flap(s), including harvesting of the flap(s), microvascular transfer, closure of donor site(s) and shaping the flap into a breast, unilateral
Breast reconstruction with deep inferior epigastric perforator (DIEP) flap or superficial inferior epigastric artery (SIEA) flap, including harvesting of the flap, microvascular transfer, closure of donor site and shaping the flap into a breast, unilateral
ICD-9 codes covered if selection criteria are met:
Acquired absence of breast [following medically necessary mastectomy or lumpectomy resulting in significant deformity]
Other ICD-9 codes related to the CPB:
Other specified disorders of breast [acquired deformity NOS]
Acquired deformity of chest and rib [pectus excavatum]
Pectus excavatum [congenital]
Other anomalies of ribs and sternum [related to Poland's syndrome]
Absence of muscle and tendon [related to Poland's syndrome]
Specified anomalies of breast [hypoplasia breast] [congenital deformity NOS]
Family history of malignant neoplasm of breast [related to prophylactic mastectomy]
The above policy is based on the following references:
Kotwall CA. Breast cancer treatment and chemoprevention. Can Fam Physician. 1999;45:1917-1924.
Polednak AP. Postmastectomy breast reconstruction in Connecticut: Trends and predictors. Plast Reconstr Surg. 1999;104(3):669-673.
Brandberg Y, Malm M, Rutqvist LE, et al. A prospective randomised study (named SVEA) of three methods of delayed breast reconstruction. Study, design, patients' preoperative problems and expectations. Scand J Plast Reconstr Surg Hand Surg. 1999;33(2):209-216.
Delay E, Jorquera F, Pasi P, Gratadour AC. Autologous latissimus breast reconstruction in association with the abdominal advancement flap: A new refinement in breast reconstruction. Ann Plast Surg. 1999;42(1):67-75.
Spear SL, Pennanen M, Barter J, Burke JB. Prophylactic mastectomy, oophorectomy, hysterectomy, and immediate transverse rectus abdominis muscle flap breast reconstruction in a BRCA- 2-positive patient. Plast Reconstr Surg. 1999;103(2):548-553; discussion 554-555.
Yeh KA, Lyle G, Wei JP, Sherry R. Immediate breast reconstruction in breast cancer: Morbidity and outcome. Am Surg. 1998;64(12):1195-1199.
Papp C, Wechselberger G, Schoeller T. Autologous breast reconstruction after breast-conserving cancer surgery. Plast Reconstr Surg. 1998;102(6):1932-1936; discussion 1937-1938.
Chavoin JP, Grolleau JL, Lanfrey E, Lavigne B. Breast reconstruction after mastectomy for cancer. Rev Prat. 1998;48(1):67-70.
Delay E, Gounot N, Bouillot A, Zlatoff P, et al. Autologous latissimus breast reconstruction: A 3-year clinical experience with 100 patients. Plast Reconstr Surg. 1998;102(5):1461-1478.
Bostwick J. Breast reconstruction after mastectomy and breast implants. Current status in the USA. Ann Chir Plast Esthet. 1997;42(2):100-106.
Salmon RJ. Evolution of the surgery of cancer of the breast. Bull Cancer. 1998;85(6):539-543.
Strozzo MD. An overview of surgical management of stage I and stage II breast cancer for the primary care provider. Lippincotts Prim Care Pract. 1998;2(2):160-169.
Hidalgo DA, Borgen PJ, Petrek JA, et al. Immediate reconstruction after complete skin-sparing mastectomy with autologous tissue. J Am Coll Surg. 1998;187(1):17-21.
Evans GR, Kroll SS. Choice of technique for reconstruction. Clin Plast Surg. 1998;25(2):311-316.
Papp C, McCraw JB. Autogenous latissimus breast reconstruction. Clin Plast Surg. 1998;25(2):261-266.
Kroll SS. Bilateral breast reconstruction. Clin Plast Surg. 1998;25(2):251-259.
Serletti JM, Moran SL. The combined use of the TRAM and expanders/implants in breast reconstruction. Ann Plast Surg. 1998;40(5):510-514.
Bhatty MA, Berry RB. Nipple-areola reconstruction by tattooing and nipple sharing. Br J Plast Surg. 1997;50(5):331-334.
Blondeel PN. One hundred free DIEP flap breast reconstructions: A personal experience. Br J Plast Surg. 1999;52(2):104-111.
Feller AM. Reconstruction of the female breast with free transverse lower abdominal flap as perforator flap. Langenbecks Arch Chir Suppl Kongressbd. 1998;115:971-972.
Hamdi M, Weiler-Mithoff EM, Webster MH. Deep inferior epigastric perforator flap in breast reconstruction: Experience with the first 50 flaps. Plast Reconstr Surg. 1999;103(1):86-95.
Blondeel PN, Boeckx WD. Refinements in free flap breast reconstruction: The free bilateral deep inferior epigastric perforator flap anastomosed to the internal mammary artery. Br J Plast Surg. 1994;47(7):495-501.
National Organization for Rare Disorders, Inc. (NORD). Poland syndrome. In: NORD Rare Disease Database. New Fairfield, CT: NORD; 1996. Availableat:http://www.stepstn.com/cgi-win/nord.exe?proc=Redirect&type=rdb_sum&id=440.htm. Accessed February 15, 2002.
Blondeel PN, Demuynck M, Mete D, et al. Sensory nerve repair in perforator flaps for autologous breast reconstruction: Sensational or senseless? Br J Plast Surg. 1999;52(1):37-44.
Blondeel N, Vanderstraeten GG, Monstrey SJ, et al. The donor site morbidity of free DIEP flaps and free TRAM flaps for breast reconstruction. Br J Plast Surg. 1997;50(5):322-330.
Nahabedian MY, Dooley W, Singh N, et al. Contour abnormalities of the abdomen after breast reconstruction with abdominal flaps: The role of muscle preservation. Plast Reconstr Surg. 2002;109(1):91-101.
Yap LH, Whiten SC, Forster A, et al. The anatomical and neurophysiological basis of the sensate free TRAM and DIEP flaps. Br J Plast Surg. 2002;55(1):35-45.
Guzzetti T, Thione A. Successful breast reconstruction with a perforator to deep inferior epigastric perforator flap. Ann Plast Surg. 2001;46(6):641-643.
Keller A. The deep inferior epigastric perforator free flap for breast reconstruction. Ann Plast Surg. 2001;46(5):474-480.
Kroll SS. Fat necrosis in free transverse rectus abdominis myocutaneous and deep inferior epigastric perforator flaps. Plast Reconstr Surg. 2000;106(3):576-583.
Sauven P; Association of Breast Surgery Family History Guidelines Panel. Guidelines for the management of women at increased familial risk of breast cancer. Eur J Cancer. 2004;40(5):653-665.
Fischbacher C. Immediate versus delayed breast reconstruction. STEER: Succint and Timely Evaluated Evidence Reviews. Bazian, Ltd., eds. London, UK: Wessex Institute for Health Research and Development, University of Southampton; 2002; 2(17):1-18.
Fischbacher C. Cosmetic breast augmentation. STEER: Succint and TImely Evaluated Evidence Reviews. Bazian, Ltd., eds. London, UK: Wessex Institute for Health Research and Development, University of Southampton; 2003:3(1):1-12.
Edlich RF, Winters KL, Faulkner BC, et al. Advances in breast reconstruction after mastectomy. J Long Term Eff Med Implants. 2005;15(2):197-207.
Fentiman IS, Hamed H. Breast reconstruction. Int J Clin Pract. 2006;60(4):471-474.
Javaid M, Song F, Leinster S, et al. Radiation effects on the cosmetic outcomes of immediate and delayed autologous breast reconstruction: An argument about timing. J Plast Reconstr Aesthet Surg. 2006;59(1):16-26.
Chang DS, McGrath MH. Management of benign tumors of the adolescent breast. Plast Reconstr Surg. 2007;120(1):13e-19e.
National Institute for Health and Clinical Excellence (NICE). Laparoscopic mobilisation of the greater omentum for breast reconstruction. Interventional Procedure Guidance 253. London, UK: NICE; 2008.
Losken A, Hamdi M. Partial breast reconstruction: Current perspectives. Plast Reconstr Surg. 2009;124(3):722-736.
Hyakusoku H, Ogawa R, Ono S, et al. Complications after autologous fat injection to the breast. Plast Reconstr Surg. 2009;123(1):360-370; discussion 371-372.
Gutowski KA; ASPS Fat Graft Task Force. Current applications and safety of autologous fat grafts: A report of the ASPS fat graft task force. Plast Reconstr Surg. 2009;124(1):272-280. Available at: http://www.plasticsurgery.org/Documents/Medical_Profesionals/Health_Policy/guiding_principles/Fat-Grafting-Task-Force-Report.pdf. Accessed February 7, 2011.
Mizuno H, Hyakusoku H. Fat grafting to the breast and adipose-derived stem cells: Recent scientific consensus and controversy. Aesthet Surg J. 2010;30(3):381-387.
Cook Biotech Incorporated. Biodesign Nipple Reconstruction Cylinder [website]. West Lafayette, IN: Cook Biotech Incoporated; 2009. Available at: http://www.cookmedical.com/sur/content/mmedia/FP0054-01C.pdf. Accessed January 24, 2012.
National Institute for Health and Clinical Excellence (NICE). Breast reconstruction using lipomodelling after breast cancer treatment. Interventional Procedure Guidance 417. London, UK: NICE; January 2012.
Phillips BT, Bishawi M, Dagum AB, et al. A systematic review of antibiotic use and infection in breast reconstruction: What is the evidence? Plast Reconstr Surg. 2013;131(1):1-13.
Claro F Jr, Figueiredo JC, Zampar AG, et al. Applicability and safety of autologous fat for reconstruction of the breast. Br J Surg. 2012;99(6):768-80.
Llewellyn-Bennett R, Greenwood R, Benson JR, et al. Randomized clinical trial on the effect of fibrin sealant on latissimus dorsi donor-site seroma formation after breast reconstruction. Br J Surg. 2012;99(10):1381-1388.
Ibrahim AM, Ayeni OA, Hughes KB, et al. Acellular dermal matrices in breast surgery: A comprehensive review. Ann Plast Surg. 2013;70(6):732-738.
Cheng A, Saint-Cyr M. Comparison of different ADM materials in breast surgery. Clin Plast Surg. 2012;39(2):167-175.
Allen RJ, Haddock NT, Ahn CY, Sadeghi A. Breast reconstruction with the profunda artery perforator flap. Plast Reconstr Surg. 2012;129(1):16e-23e.
DellaCroce FJ, Sullivan SK, Trahan C, Jenkins CE. Body lift perforator flap breast reconstruction: A review of 100 flaps in 25 cases. Plast Reconstr Surg. 2012;129(3):551-561.
Morris D. Principles of grafts and flaps for reconstructive surgery. Last reviewed December 2013. UpToDate Inc., Waltham, MA.
Nahabedian M. Breast reconstruction in women with breast cancer. Last reviewed December 2013. UpToDate Inc., Waltham, MA.
Tanna N, Broer PN, Weichman KE, et al. Microsurgical breast reconstruction for nipple-sparing mastectomy. Plast Reconstr Surg. 2013;131(2):139e-147e.
Levine SM, Snider C, Gerald G, et al. Buried flap reconstruction after nipple-sparing mastectomy: Advancing toward single-stage breast reconstruction. Plast Reconstr Surg. 2013;132(4):489e-497e.
Weichman KE, Broer PN, Tanna N, et al. The role of autologous fat grafting in secondary microsurgical breast reconstruction. Ann Plast Surg. 2013;71(1):24-30.
Healy C, Allen RJ Sr. The evolution of perforator flap breast reconstruction: Twenty years after the first DIEP flap. J Reconstr Microsurg. 2013 Oct 25. [Epub ahead of print]
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.